Application of paclitaxel as adjuvant treatment for benign cicatricial airway stenosis.
- Author:
Xiao-Jian QIU
1
;
Jie ZHANG
2
;
Juan WANG
1
;
Yu-Ling WANG
1
;
Min XU
1
Author Information
1. Department of Pulmonary Medicine, Beijing Tian Tan Hospital, Capital Medical University, Beijing, 100050, China.
2. Department of Pulmonary Medicine, Beijing Tian Tan Hospital, Capital Medical University, Beijing, 100050, China. zhangj_tt@163.com.
- Publication Type:Journal Article
- Keywords:
benign cicatricial airway stenosis;
bronchoscopy;
complications;
efficacy;
paclitaxel
- MeSH:
Adolescent;
Adult;
Aged;
Bronchi;
pathology;
Chemotherapy, Adjuvant;
adverse effects;
Cicatrix;
complications;
drug therapy;
surgery;
Female;
Humans;
Male;
Middle Aged;
Paclitaxel;
administration & dosage;
adverse effects;
therapeutic use;
Postoperative Complications;
Respiratory Insufficiency;
drug therapy;
etiology;
surgery;
Tracheal Stenosis;
drug therapy;
etiology;
surgery;
Tracheotomy;
adverse effects
- From:
Journal of Huazhong University of Science and Technology (Medical Sciences)
2016;36(6):817-822
- CountryChina
- Language:English
-
Abstract:
Benign cicatricial airway stenosis (BCAS) is a potentially life-threatening disease. Recurrence occurs frequently after endoscopic treatment. Paclitaxel is known to prevent restenosis, but its clinical efficacy and safety is undetermined. Therefore, in this study, we investigated the efficacy and associated complications of paclitaxel as adjuvant treatment for BCAS of different etiologies. The study cohort included 28 patients with BCAS resulting from tuberculosis, intubation, tracheotomy, and other etiologies. All patients were treated at the Department of Respiratory Diseases, Beijing Tian Tan Hospital, Capital Medical University, China, between January 2010 and August 2014. After primary treatment by balloon dilation, cryotherapy, and/or high-frequency needle-knife treatment, paclitaxel was applied to the airway mucosa at the site of stenosis using a newly developed local instillation catheter. The primary outcome measures were the therapeutic efficacy of paclitaxel as adjuvant treatment, and the incidence of complications was observed as well. According to our criteria for evaluating the clinical effects on BCAS, 24 of the 28 cases achieved durable remission, three cases had remission, and one case showed no remission. Thus, the durable remission rate was 85.7%, and the combined effective rate was 96.4%. No differences in outcomes were observed among the different BCAS etiologies (P=0.144), and few complications were observed. Our results indicated that paclitaxel as an adjuvant treatment has greater efficacy than previously reported BCAS treatment methods.
